A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Journal Information
Full Title: J Immunother Cancer
Abbreviation: J Immunother Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"data availability statement data are available on reasonable request. ethics statements patient consent for publication not applicable. tnbc biopsy samples were provided by the biological resource center (biobank number bb-0033"
"Competing interests: None declared."
"Funding: This work was supported by a public grant overseen by the French National Research Agency (ANR) as part of the “Investissements d’Avenir” program (reference: LabEx MabImprove ANR-10-LABX-53- 01), University of Montpellier, Inserm Transfert, Région Occitanie, the association "Ligue Régionale du Gard CD30", "Ligue Régionale de l’Herault CD34", and "Ligue Régionale de la Charente Maritime CD17"."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025